Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870726 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01870726 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT01870726, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous deletion of PTEN or PTEN negative by IHC. In addition, the anti-tumor activity of INC280 single agent should have been assessed in patients with recurrent glioblastoma with c-Met alteration.
Interventions
- DRUG Buparlisib
- DRUG INC280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-01-09 |
| Est. Completion | 2016-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870726
The ClinicalTrials.gov registry entry for NCT01870726 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Buparlisib is the first listed.
NCT01870726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870726 about?
NCT01870726 is a clinical study titled "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma". The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous deletion of PTEN or PTEN negative by IHC. In addition, the anti-tumor activi...
What is the current status of trial NCT01870726?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2014-01-09. Estimated completion is 2016-12-23.
What interventions are being tested in trial NCT01870726?
The interventions under investigation include: Buparlisib (DRUG), INC280 (DRUG).
Who is sponsoring clinical trial NCT01870726?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.